Search
Search Results
##search.searchResults.foundPlural##
-
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1337PDF: 1106HTML: 246 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7790PDF: 2473HTML: 2113Table 1.: 239Table 2.: 249Table 3.: 232Table 4.: 226 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3495PDF: 1410HTML: 2715 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2607PDF: 875HTML: 9054Efremov 1: 250Efremov 2: 213 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3489PDF: 2309HTML: 23480Untitled: 225Untitled: 238Untitled: 249 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
1968PDF: 815HTML: 562 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1434PDF: 834HTML: 1027 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2682PDF: 1663HTML: 2444Table1: 210 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4552PDF: 1675HTML: 4246Tables and Images: 255 -
VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS
3858PDF: 1637HTML: 8228Randi Fig: 200 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1521PDF: 939Suppl. Files: 470HTML: 293 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2980PDF: 1405HTML: 3722Untitled: 212Untitled: 226Untitled: 197 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2045PDF: 1399HTML: 799 -
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
1386PDF: 787HTML: 4410Figure 1: 177Untitled: 157Untitled: 212 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
985PDF: 544HTML: 219 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
2229PDF: 750HTML: 2144Untitled: 242Untitled: 169Untitled: 193Untitled: 171Untitled: 186Untitled: 199Untitled: 199 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3468PDF: 1326HTML: 2309Fi.1 Gritti.Rambaldi: 227 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1637PDF: 1089HTML: 440 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2446PDF: 1026HTML: 1656Fig 1: 207Tab I: 232Cover Letter: 231 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4053PDF: 1085HTML: 3895Untitled: 187Cneo. Fig.1: 122Untitled: 115Untitled: 144Untitled: 148







